<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="59537">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02330926</url>
  </required_header>
  <id_info>
    <org_study_id>MENAC-2013-05</org_study_id>
    <secondary_id>2013-002282-19</secondary_id>
    <nct_id>NCT02330926</nct_id>
  </id_info>
  <brief_title>Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy</brief_title>
  <acronym>MENAC</acronym>
  <official_title>A Randomised, Open-label Trial of a Multimodal Intervention (Exercise, Nutrition and Antiinflammatory Medication) Plus Standard Care Versus Standard Care Alone to Prevent/Attenuate Cachexia in Advanced Cancer Patients Undergoing Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ottawa Regional Cancer Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cross Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Beatson West of Scotland Cancer Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen Margaret Hospital, Dunfermline</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK Edinburgh Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Malteser Krankenhaus Seliger Gerhardt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tumor Biology Center Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer cachexia is a multi-factorial syndrome defined by an ongoing loss of skeletal muscle
      mass (with or without loss of fat mass) that cannot be fully reversed by conventional
      nutritional support and leads to progressive functional impairment.

      There is an urgency for improving management, but there is no consensus on the optimal
      treatment for cancer cachexia. Several single therapies for cancer cachexia have been
      examined in clinical trials, with disappointing overall results. As multiple factors are
      responsible for the development of cachexia, it has been argued that optimal cachexia
      interventions should target all components: multimodal therapy for a multimodal problem.

      The overall aim of this study is to early prevent the development of cachexia rather than
      treatment late in the disease trajectory. From a patient perspective a short term effect
      will be to improve physical and psychological function, to reduce symptom burden and to
      improve survival. In other words live a longer and better life during and after
      chemotherapy. Direct effects of the cachexia intervention are expected to be reduction of
      weight and muscle loss, and improved physical activity and quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>body weight change</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Cachexia</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>multimodal intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard care plus multimodal intervention consisting of nutritional supplements and advice, home-based self-assisted exercise program, and anti-inflammatory medication (ibuprofen)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard palliative care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard care</intervention_name>
    <arm_group_label>multimodal intervention</arm_group_label>
    <arm_group_label>standard care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nutritional supplements and advice</intervention_name>
    <arm_group_label>multimodal intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>home-based self-assisted exercise program</intervention_name>
    <arm_group_label>multimodal intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <arm_group_label>multimodal intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of lung cancer, pancreatic cancer or cholangiocarcinoma where the diagnosis
             is based on histological, radiological or multidisciplinary team (MDT) evaluation

          -  non-small cell lung cancer (stage III or IV), small cell lung cancer (extensive
             stage) or pancreatic adenocarcinoma (stage III or IV) or non-operable
             cholangiocarcinoma, due to commence first or second line anticancer treatment
             (defined as chemotherapy or chemo-radiotherapy or targeted therapy

          -  staging CT within 4 weeks of commencement of anti-cancer therapy (in patients where
             staging CT is out-with this period, further CT scanning will be undertaken. PETCT's
             are also appropriate)

          -  completed all other baseline assessments within one week prior to first course of
             anti-cancer treatment

          -  written informed consent

          -  able to comply with trial interventions (in the opinion of referring clinician) e.g.
             willing and able to do light exercise and take oral nutritional supplements as well
             as no major contraindications against ibuprofen.

          -  Karnofsky Performance Status &gt;70

        Exclusion Criteria:

          -  Neuro-endocrine pancreatic cancer

          -  Creatinine clearance &lt;30ml/min

          -  Receiving parenteral nutrition or enteral nutrition via feeding tube

          -  receiving neo-adjuvant anti-cancer therapy

          -  BMI &gt;30 kg/m2

          -  Use of appetite stimulants or anabolic/anti-catabolic agents (such as megestrol
             acetate, progestational agents, marijuana growth hormone, dronabinol, or other
             anabolic agent) within 30 days prior to study baseline

          -  Concomitant steroid (&gt;10mg/d prednisolone or equivalent) treatment for less than
             three months prior to inclusion (inhaled, optical or pulsed oral steroids (up to 10
             days use) are permitted)

          -  Concomitant long term (&gt;1 week) nonsteroidal anti-inflammatory drugs (NSAID) or
             aspirin treatment

          -  pregnancy, breast-feeding or of child bearing potential (that is not postmenopausal
             or permanently sterilised) age and not using adequate contraception (oral, injected,
             implanted or hormonal methods of contraception, intrauterine device and barrier
             method)

          -  Concomitant anti-coagulant treatment (e.g. warfarin or heparin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stein Kaasa, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ken Fearon, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh, Royal Infirmary of Edinburgh, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trude R Balstad, PhD</last_name>
    <email>trude.r.balstad@ntnu.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tora S Solheim, MD PhD</last_name>
    <email>tora.l.skeidsvoll@ntnu.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cross Cancer Insitute</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Page</last_name>
      <email>napage@toh.ca</email>
    </contact>
    <investigator>
      <last_name>Quincy Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Page</last_name>
      <email>napage@toh.ca</email>
    </contact>
    <investigator>
      <last_name>Thimothy Asmis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aasta Bye, MD, PhD</last_name>
      <email>asta.bye@hioa.no</email>
    </contact>
    <investigator>
      <last_name>Nina Aass, MD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trude R Balstad, PhD</last_name>
      <email>trude.r.balstad@ntnu.no</email>
    </contact>
    <investigator>
      <last_name>Tora S Solheim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edinburgh Cancer Centre</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Madden</last_name>
      <email>menac@ac.soton.uk</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Hutchings</last_name>
      <email>menac@ac.soton.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Barry Laird</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Margaret Hospital</name>
      <address>
        <city>Fife</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacke Madden</last_name>
      <email>menac@ac.soton.uk</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Hutchings</last_name>
      <email>menac@ac.soton.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Joanna Bowden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Madden</last_name>
      <email>menac@soton.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Hutchings</last_name>
      <email>menac@soton.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Janet Graham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Norway</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 4, 2017</lastchanged_date>
  <firstreceived_date>December 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Combined modality treatment</keyword>
  <keyword>Diet therapy</keyword>
  <keyword>Exercise therapy</keyword>
  <keyword>Ibuprofen</keyword>
  <keyword>Dietary supplements</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
